Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

Abroad (travel likely)Recruiting

Conditions

Type 1 Diabetes

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Investigational Site Number: 0560001, Leuven, Belgium
Investigational Site Number: 2500001, Bron, France
Investigational Site Number: 2500003, Paris, France
Investigational Site Number: 2500002, Paris, France
Investigational Site Number: 3800001, Ancona, Italy
Investigational Site Number: 3800003, Palermo, Italy
Investigational Site Number: 7240001, Madrid, Spain
Investigational Site Number: 7240002, Madrid, Spain
Investigational Site Number: 7240003, Zaragoza, Spain
Investigational Site Number: 8260001, Birmingham, United Kingdom
Investigational Site Number: 8260002, London, United Kingdom

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

Type 1 Diabetes Mellitus

Abroad (travel likely)RecruitingPHASE2

Ichikawa, Japan · Sapporo, Japan

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Type 1 Diabetes Mellitus

IsraelRecruitingPHASE3

Scottsdale, United States · Huntington Beach, United States

Pediatric Artificial Intelligence for Retinopathy Screening in Children With Type 1 Diabetes

Type 1 Diabetes Mellitus

Abroad (travel likely)Recruiting

Prague, Czechia

ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

Type 1 Diabetes · Type 2 Diabetes · Cystic Fibrosis-related Diabetes

Abroad (travel likely)Recruiting

Baltimore, United States